Pilot RECAP Study in Healthy Volunteers (RECAP)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04842045|
Recruitment Status : Recruiting
First Posted : April 12, 2021
Last Update Posted : May 16, 2022
|Condition or disease||Intervention/treatment||Phase|
|Psychedelic Experiences Amnesia||Drug: Psilocybin and Midazolam||Phase 1|
The PILOT RECAP Study will investigate the effect of co- administering the amnestic agent midazolam with a single 25 mg dose of psilocybin on the induction of a psychedelic experience and subsequent memory for the experience with the goal of identifying an optimal dosing regimen of midazolam that will allow a psychedelic experience to occur while also inducing amnesia for the experience. Identifying this midazolam dosing regimen will allow us in a subsequent stage of the RECAP program to test whether memory for the psychedelic experience is required/important for psilocybin to produce longer-term antidepressant effects. This is a phase 1 study in psychiatrically and medically healthy volunteers. Given this, there is no disease background for PILOT RECAP per se. However, the purpose of PILOT RECAP is to identify an optimal midazolam dosing schedule to be used in a subsequent study (RECAP) in patients with major depressive disorder (MDD).
The investigational treatment for PILOT RECAP is a single 25 mg dose of psilocybin combined with repeated intravenous (IV) boluses of midazolam dosed at levels known to maintain conscious experience while inducing subsequent amnesia for the experience upon its conclusion. Because PILOT RECAP is the first study to examine this drug combination, no data are currently available on this approach. Psilocybin + midazolam will be administered within a "Set and Setting" (SaS) protocol that provides psychoeducation and therapeutic support prior to, during, and following psychedelic dosing, and that has been standard procedure for recent studies of psilocybin in humans. It is believed that this SaS approach enhances clinical efficacy and safety. SaS is an integral component of the PILOT RECAP intervention.
The PILOT RECAP study will not enroll vulnerable populations. During this study, participants are asked to:
- Refrain from use of psychotropic medications. Use of such medications prior to psilocybin/midazolam dosing will result in a participant being discontinued from the study.
- Refrain from use of any illegal psychoactive substances from screening until study termination.
Refrain from using legal psychoactive substance for the following defined time periods (the exception is caffeine):
- Tobacco and Nicotine: from screening until study termination
- Alcohol: 72 hours prior to the Dosing Visit
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||12 participants|
|Intervention Model:||Single Group Assignment|
|Intervention Model Description:||Open trial of a single 25 mg dose of psilocybin combined with repeated boluses of midazolam in medically and psychiatrically healthy volunteers.|
|Masking:||None (Open Label)|
|Official Title:||Recall of Experience and Conscious Awareness in Psilocybin Treatment of Depression (The RECAP Study): Pilot Phase in Healthy Adult Volunteers|
|Actual Study Start Date :||May 21, 2021|
|Estimated Primary Completion Date :||April 2023|
|Estimated Study Completion Date :||December 2023|
Experimental: Single Arm
Medically and psychiatrically healthy adults ages 21 to 65 years will receive a single 25 mg dose of psilocybin combined with repeated boluses of midazolam administered in a clinically supportive setting.
Drug: Psilocybin and Midazolam
The psilocybin used in this study is synthetically manufactured in a laboratory and meets quality specifications suitable for human research use. The active drug is encapsulated using a hydroxypropyl methylcellulose (HPMC) capsule and contains 25 mg of psilocybin.
The midazolam in this study will be administered intravenously. The total dose administered to a given subject is dependent on the individual's level of amnesia, sedation scale score, age, and weight.
- Number of participants scoring >50 percent of normative scores on selected questions from the Altered States of Consciousness (ASC) questionnaire asked during the dosing session Day 0. [ Time Frame: On Day 14 ]
Participants will complete a selection of several questions from the ASC questionnaire that strongly associate positively or negatively with later antidepressant effect of psilocybin in patients with treatment resistant depression or capture classic features of the psychedelic experience.
During the dosing session, investigator will repeatedly ask selected items from the ASC scale to get a "real time" measure of what the participants are experiencing. Each of these items will be scored separately. Higher score are indicative of a more intense psychedelic experience.
- Number of participants scoring < 50 percent on post-dosing Day 1 of the mean normative score of ASC data from healthy volunteers administered the ASC questionnaire post-dosing [ Time Frame: On Day 15 ]
To assess the degree to which midazolam has induced amnesia for the psychedelic experience, participants will complete the full ASC.
The ASC is a 94 item questionaire. In response to each item, participants are asked to mark their experience somewhere between 'No, not more than usual' to 'Yes, much more than usual'. Normal waking consciousness corresponds to a mark at the very left end of the scale, i.e. 'No, Not more than usual'.
Responses marked more towards right side of the range are considered high on psychedelic experience.
- Accuracy on post-dosing Day 1 in recognizing ASC items asked during the dosing session Day 0 (number of correct versus distractor items) [ Time Frame: On Day 15 ]Participants will undergo a yes-no ASC recognition task regarding their memory for internally and externally focused phenomenological content of their experience.
- Safety of psilocybin-midazolam co-administration assessed by number of adverse event incidences in each severity grade. [ Time Frame: up to 4 weeks ]Adverse event grading will be done using Common Terminology Criteria for Adverse Event (CTCAE)Adverse events will be graded from Grade 1-5 depending on severity. Grade 1 - mild, grade 2 - moderate, grade 3 - severe, grade 4 - Life threatening, grade 5 - Fatal. Adverse events will be collected on an Adverse Event Log throughout the study.
- Safety of psilocybin-midazolam co-administration assessed by number of participants requiring medical attention due to adverse events [ Time Frame: up to 4 weeks ]
- Safety of psilocybin-midazolam co-administration assessed by number of participants requiring psychiatric attention due to adverse events [ Time Frame: up to 4 weeks ]
- Safety of psilocybin-midazolam co-administration assessed by number of participants leading to withdrawal from study due to adverse events [ Time Frame: up to 4 weeks ]
- Safety of psilocybin-midazolam co-administration assessed by number of participants with severe adverse events [ Time Frame: up to 4 weeks ]
- Safety of psilocybin-midazolam co-administration assessed by number of participants with new concomitant medication due to adverse events [ Time Frame: up to 4 weeks ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04842045
|Contact: Kristin Van Hyfteemail@example.com|
|Contact: Christopher R Nicholas, MD,PHDfirstname.lastname@example.org|
|United States, Wisconsin|
|UWHealth, 600 Highland Avenue||Recruiting|
|Madison, Wisconsin, United States, 53792|
|Contact: Kristin Van Hyfte 608-263-1739 email@example.com|
|Principal Investigator: Christopher R Nicholas, MD,PHD|
|Principal Investigator:||Christopher R Nicholas, MD,PHD||University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United State, 53715|